DMX – DelMar Pharmaceuticals Inc.

Latest News & Stock Analysis

DelMar Pharmaceuticals Inc., trading under the ticker DMX, is a biopharmaceutical company focused on developing and commercializing new cancer therapies. The company’s primary focus is on developing VAL-083, a novel DNA-targeting agent, for the treatment of various cancers, including glioblastoma multiforme (GBM). DelMar Pharmaceuticals aims to address unmet medical needs in oncology by providing innovative treatment options. Investors interested in biotechnology stocks and cancer treatment advancements may find DMX an interesting investment. Stay updated with the latest news on DMX and market trends affecting the pharmaceutical sector to make informed investment decisions. Keep abreast of stock analysis and company developments to understand the potential of DMX stocks.

District Metals: Unveiling a Giant Uranium Deposit in Sweden
DMX

District Metals: Unveiling a Giant Uranium Deposit in Sweden

by | 03/05/2025 09:00 PM | DMX

🌍 A new resource estimate confirms its Viken project in Sweden as the second-largest uranium deposit on the planet.

📊 The deposit is massive, containing over 3.5 billion tonnes of ore, translating to over a billion pounds of uranium.

🇸🇪 The project's future development hinges entirely on the potential lifting of the uranium mining ban currently in place in Sweden.

Read more!